Literature DB >> 15959454

Progress in measles control--Zambia, 1999-2004.

.   

Abstract

Zambia, a southern African country with estimated population of 11.6 million in 2005, reported 1,698-23,518 measles cases annually during 1991-1999. During that period, measles was considered one of the five major causes of morbidity and mortality among children aged <5 years. During 1999-2004, the challenge of controlling measles led Zambia to try several strategies in succession. In addition to a single dose of measles vaccine offered at age 9 months through routine services, in 1999, measles supplemental immunization activities (SIAs) targeting children aged 9 months-4 years were held in four urban centers. Those activities were followed in 2000 by a subnational measles SIA targeting children aged 9 months-4 years in approximately half of the country's 72 districts. In 2003, Zambia adopted a strategy of accelerated measles control that included strengthening routine vaccination, providing a second opportunity for measles immunization for all children, and conducting case-based surveillance. As part of this strategy, a nationwide measles SIA targeting all children aged 6 months-14 years was conducted in 2003. This report summarizes progress in measles control in Zambia during 1999--2004, as measured through surveillance data, which demonstrates a marked reduction in measles transmission after the 2003 SIA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959454

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  2 in total

1.  Suppression of human immunodeficiency virus type 1 viral load during acute measles.

Authors:  William J Moss; Susana Scott; Zaza Ndhlovu; Mwaka Monze; Felicity T Cutts; Thomas C Quinn; Diane E Griffin
Journal:  Pediatr Infect Dis J       Date:  2009-01       Impact factor: 2.129

2.  Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia.

Authors:  Kalonde Malama; Amanda Tichacek; Hilary Kelly; Rachel Parker; Mubiana Inambao; Tyronza Sharkey; Kristin M Wall; William Kilembe; Matt A Price; Pat Fast; Fran Priddy; Susan Allen
Journal:  Hum Vaccin Immunother       Date:  2022-04-21       Impact factor: 4.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.